Maria-Victoria Mateos

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 80 Citations 36,555 645 World Ranking 11656 National Ranking 160

Overview

What are the main themes of his work throughout his whole career to date

His Multiple myeloma study frequently draws connections to adjacent fields such as Daratumumab. His research combines Bortezomib and Daratumumab. He undertakes interdisciplinary study in the fields of Bortezomib and Multiple myeloma through his research. Maria-Victoria Mateos connects Oncology with Intensive care medicine in his study. Maria-Victoria Mateos performs integrative study on Intensive care medicine and Oncology. Borrowing concepts from Proteasome inhibitor, he weaves in ideas under Carfilzomib. He performs multidisciplinary study on Proteasome inhibitor and Carfilzomib in his works. His studies link Disease with Internal medicine. His research on Disease often connects related topics like Internal medicine.

Maria-Victoria Mateos most often published in these fields:

Multiple myeloma (100.00%)
Oncology (100.00%)
Carfilzomib (100.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

3617 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2329 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1673 Citations

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo;Asher Chanan-Khan;Katja Christina Weisel;Ajay K Nooka.
The New England Journal of Medicine (2016)

1358 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1318 Citations

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Leukemia (2009)

913 Citations

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal.
The Lancet (2016)

828 Citations

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

María-Victoria Mateos;Meletios A. Dimopoulos;Michele Cavo;Kenshi Suzuki.
The New England Journal of Medicine (2017)

783 Citations

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Blood (2016)

721 Citations

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P. Moreau;J. San Miguel;P. Sonneveld;M. V. Mateos.
Annals of Oncology (2010)

679 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Maria-Victoria Mateos